ProQR Therapeutics N.V. (PRQR) Given Consensus Recommendation of “Buy” by Brokerages
ProQR Therapeutics N.V. (NASDAQ:PRQR) has received a consensus rating of “Buy” from the six brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $19.38.
A number of brokerages have issued reports on PRQR. Zacks Investment Research raised shares of ProQR Therapeutics N.V. from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a research note on Wednesday, August 30th. ValuEngine raised shares of ProQR Therapeutics N.V. from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of ProQR Therapeutics N.V. in a research note on Tuesday, September 26th. Chardan Capital reaffirmed a “neutral” rating on shares of ProQR Therapeutics N.V. in a research note on Sunday, September 17th. Finally, JMP Securities increased their price objective on ProQR Therapeutics N.V. from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, September 26th.
Shares of ProQR Therapeutics N.V. (PRQR) opened at 4.60 on Wednesday. ProQR Therapeutics N.V. has a 52 week low of $3.65 and a 52 week high of $8.70. The firm’s market capitalization is $110.88 million. The firm’s 50-day moving average price is $5.20 and its 200 day moving average price is $5.05.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Janus Henderson Group PLC bought a new stake in ProQR Therapeutics N.V. during the second quarter worth approximately $2,028,000. Artal Group S.A. raised its position in shares of ProQR Therapeutics N.V. by 25.0% in the second quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock valued at $2,600,000 after purchasing an additional 100,000 shares during the period. Finally, Redmile Group LLC raised its position in shares of ProQR Therapeutics N.V. by 2.8% in the second quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock valued at $8,301,000 after purchasing an additional 43,050 shares during the period. Hedge funds and other institutional investors own 35.93% of the company’s stock.
About ProQR Therapeutics N.V.
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).
Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with MarketBeat.com's FREE daily email newsletter.